Sigma's Double-Digit EPS Growth Lures New Bull -- Market Talk

Dow Jones
11/20

0111 GMT - Sigma Healthcare gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com)

 

(END) Dow Jones Newswires

November 19, 2025 20:11 ET (01:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10